SCHEMBL6652473

SCHEMBL6652473

COCOc1ccc(/C=C(\COC)C(=O)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.41
PTGS2 P35354 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
NR1H4 Q96RI1 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 1/20 0.36
FFAR1 O14842 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 2/20 0.36
THRB P10828 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GRIK1 P39086 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6652477 1.00 ALOX5 (0.41) ALOX5PTGS2CYP3A4CYP2C9NR1H4
SCHEMBL263163 0.80 CYP3A4 (0.58) CYP3A4CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL6653102 0.80 PPARA (0.39) ALOX5PTGS2NR1H4KDM4ERAB9A
SCHEMBL6651719 0.80 TBXAS1 (0.43) PTGS2NR1H4KDM4EMAPTTHRB
SCHEMBL6653106 0.80 PPARA (0.39) ALOX5PTGS2NR1H4KDM4ERAB9A
SCHEMBL6679560 0.80 PTGS2 (0.39) PTGS2NR1H4ALDH1A1KDM4ENPC1
SCHEMBL6679564 0.80 PTGS2 (0.39) PTGS2NR1H4ALDH1A1KDM4ENPC1
SCHEMBL6651712 0.80 TBXAS1 (0.43) PTGS2NR1H4KDM4EMAPTTHRB
SCHEMBL1185309 0.75 CASP1 (0.39) ALOX5ALDH1A1KDM4ENPC1RAB9A
SCHEMBL1185307 0.75 CASP1 (0.39) ALOX5ALDH1A1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254241-A1 Enzyme inhibitor; cognition activators KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-12-16 US disclosed
EP-1431280-A1 ARYL SULFAMATE DERIVATIVES Kyowa Hakko Kogyo Co., Ltd (JP) 2004-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254241-A1 Enzyme inhibitor; cognition activators SULT1A1, STS, CYP26A1 ALOX5 1939/4885PTGS2 3492/4885CYP3A4 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.